Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Market Closed 12-20 16:00:00 EST

308.44

+15.03

+5.12%

盘后308.44

+0.00+0.00%

19:18 EST

High312.52	Low293.00	Vol716.80K
Open294.00	D1 Closing293.41	Amplitude6.65%
Mkt Cap6.73B	Tradable Cap3.24B	Total Shares21.81M
T/O218.92M	T/O Rate6.83%	Tradable Shares10.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":308.44,"timestamp":1734728400000,"preClose":293.41,"halted":0,"volume":716801,"hourTrading":{"tag":"盘后","latestPrice":308.4395,"preClose":308.44,"latestTime":"19:18 EST","volume":36123,"amount":11141305.2325,"timestamp":1734740327127},"delay":0,"floatShares":10488982,"shares":21810407,"eps":-25.017162,"marketStatus":"Market Closed","change":15.03,"latestTime":"12-20 16:00:00 EST","open":294,"high":312.5199,"low":293,"amount":218918680.83468,"amplitude":0.066528,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-25.017162,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":293.41,"preHourTrading":{"tag":"盘前","latestPrice":293.77,"preClose":293.41,"latestTime":"09:29 EST","volume":423,"amount":123971.33835,"timestamp":1734704999999},"postHourTrading":{"tag":"盘后","latestPrice":308.4395,"preClose":308.44,"latestTime":"19:18 EST","volume":36123,"amount":11141305.2325,"timestamp":1734740327127},"volumeRatio":1.8889151892565612,"impliedVol":0.579,"impliedVolPercentile":0.4286},"requestUrl":"/m/hq/s/MDGL","defaultTab":"news","newsList":[{"id":"2492090403","title":"Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2492090403","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492090403?lang=en_us&edition=fundamental","pubTime":"2024-12-18 19:22","pubTimestamp":1734520960,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis  in the United States. With the latest financial year loss of US$374m and a trailing-twelve-month loss of US$519m, the US$6.8b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Madrigal Pharmaceuticals' path to profitability – when will it breakeven?We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 15% of equity. This means that it has predominantly funded its operations from equity capital, and its low deb","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-inc-nasdaq-mdgl-112240731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","BK4585","QLD","NVIW.SI","PSQ","IE00BKPKM429.USD","MNQmain","MDGL","IE00B64PRP62.GBP","LU2095319765.USD","USJW.SI","QID","USAW.SI","NQmain","NDAQ","SQQQ","TQQQ","IE00B3QW5Z07.USD","BK4588","TSYW.SI","LU2210149790.SGD","LU2210150020.SGD","BK4139","BK4112",".IXIC"],"gpt_icon":1},{"id":"2492692497","title":"Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492692497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492692497?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:50","pubTimestamp":1734501010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","ARCT","MDGL","BK4137","HCSG","BK4588"],"gpt_icon":0},{"id":"2489237474","title":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2489237474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489237474?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:02","pubTimestamp":1733500955,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'** Drug developer Sagimet Biosciences' SGMT.O shares rise 8.4% to $5.05** Oppenheimer starts coverage with \"outperform\" rating and PT at $30 — a 543.8% premium to Thursday's close of $4.66** Brokerage sees \"underappreciated opportunity\" in co's lead experimental drug, denifanstat, being developed to treat metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** The MASH market is dominated by Madrigal Pharmaceuticals' MDGL.O Rezdiffra** \"We see SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve,\" brokerage says ** Oppenheimer expects risk-adjusted peak total revenues of ~$1.9 bln for denifanstat in 2040      ** Including session's move, stock down 8.5% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3N3N70WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","MDGL"],"gpt_icon":0},{"id":"2489851522","title":"Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2489851522","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489851522?lang=en_us&edition=fundamental","pubTime":"2024-12-06 19:46","pubTimestamp":1733485607,"startTime":"0","endTime":"0","summary":"JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals  to $427 from $415 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Paulson takes new stake in Southwestern Energy, exits AngloGold Ashanti. Biotech Alert: Searches spiking for these stocks today. Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-price-target-raised-114647437.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-price-target-raised-114647437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDGL","JMP"],"gpt_icon":0},{"id":"2486396729","title":"Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486396729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486396729?lang=en_us&edition=fundamental","pubTime":"2024-11-28 18:01","pubTimestamp":1732788061,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Madrig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-axsome-therapeutics-axsm-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-axsome-therapeutics-axsm-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","MDGL","AXSM","BK4007","BK4585","BK4139","BK4588","BK4505","HCSG"],"gpt_icon":0},{"id":"2485205923","title":"3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2485205923","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485205923?lang=en_us&edition=fundamental","pubTime":"2024-11-23 19:46","pubTimestamp":1732362360,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals is working to expand its markets and roll out its first drug.Sales of its medicine look good so far, and there isn't any competition yet.Developing a competitive advantage may also be in the cards.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798493%2Ftwo-investors-consider-a-laptop.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798493%2Ftwo-investors-consider-a-laptop.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/11/23/3-reasons-why-buying-madrigal-pharmaceuticals-is-a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4588","BK4139","BK4585","MDGL"],"gpt_icon":0},{"id":"2485730295","title":"Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485730295","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485730295?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:55","pubTimestamp":1732287307,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.  reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a \"golden cross.\". A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.A successful golden cross event has three stages. It first begins when a stock's price on the decline bottoms out. Then, its shorter moving average crosses above its longer moving average, triggering a positive trend reversal. The third and final phase occurs when the stock maintains its upward momentum.This kind of chart pattern is the opposite of a death cross, which is a technical event ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-mdgl-just-flashed-golden-145507143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDGL","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2485042402","title":"Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485042402","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485042402?lang=en_us&edition=fundamental","pubTime":"2024-11-22 06:12","pubTimestamp":1732227140,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024.In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.  stands against the other biotech stocks.Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth. Contrary to Holz's perspective, 2024 has started off strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate  of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate  and reach $232 billion by 2032.“We still see tailwinds for the industry going forward. Smaller-cap names are still targets for acquisitions by bigger biopharma firms, and a wave of acquisitions has continued since late las","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jtCaEnP6EKRgpGDacKXjjw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cfa181625bc50a71fdc5dd9e1953061","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jtCaEnP6EKRgpGDacKXjjw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cfa181625bc50a71fdc5dd9e1953061"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-madrigal-pharmaceuticals-inc-mdgl-221220517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID",".IXIC","BK4585","CAGR","BK4159","PSQ","SQQQ","MDGL","TQQQ","QLD","BK4139","MNQmain","BK4588","NQmain"],"gpt_icon":1},{"id":"2485122429","title":"Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra","url":"https://stock-news.laohu8.com/highlight/detail?id=2485122429","media":"seekingalpha","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485122429?lang=en_us&edition=fundamental","pubTime":"2024-11-21 03:02","pubTimestamp":1732129336,"startTime":"0","endTime":"0","summary":"Rasi Bhadramani The promising results released on Nov. 19 from Novo Nordisk  on GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis  could spell trouble for Madrigal Pharmaceuticals'  Rezdiffra . That's the assessment from Cantor Fitzgerald analyst Prakhar Agrawal, who says that \"it is becoming increasingly clear that semaglutide will be the first-line therapy in MASH once approved in 2026, based on our several checks with physicians and payors.\"  He added that while some who are bullish on Madrigal contend that a decline in new patients on Rezdiffra will be outweighed by an increase in newly diagnosed MASH patients who will eventually switch to Rezdiffra, they are mistaken based on checks with key opinion leaders. Agrawal sees a 10%-40% downside to Street estimates beginning in 2026. Evercore ISI's Liisa Bayko, however, has a different view, saying she doesn't see the semaglutide data as \"changing the trajectory for Rezdiffra.\" She added that","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1178017792/image_1178017792.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1178017792/image_1178017792.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4313317-novo-semaglutide-data-mash-negatively-impact-madrigals-rezdiffra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","MDGL","BK4585","BK4588"],"gpt_icon":0},{"id":"2485912587","title":"Madrigal Pharmaceuticals price target raised to $400 from $350 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485912587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485912587?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:06","pubTimestamp":1732125972,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $400 from $350 and keeps an Outperform rating on...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-raised-to-400-from-350-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-raised-to-400-from-350-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","MDGL"],"gpt_icon":0},{"id":"2485114959","title":"Trump Media saw the largest increase in short interest in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2485114959","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485114959?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:57","pubTimestamp":1732118245,"startTime":"0","endTime":"0","summary":"hyejin kang/iStock via Getty Images Trump Media & Technology (DJT) and Lucid Group (LCID) saw the largest increases in short interest in October, while Expand Energy Corp. (EXE), and Pilgrim’s Pride (","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312369-trump-media-saw-the-largest-increase-in-short-interest-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ODFL","SIRI","SWKS","DJT","CRC","CG","GAP.AU","FOUR","CORT","EAT","AAL.AU","MDGL","NTRA","AMTM","DOCU","IWV","BIRK","LINE","XLP","HUM.AU","RBC","VRNS","WEX","ADC.AU","ADC","ENPH","PPC","LCID","VERX","XLU","GAP","CART","MC","CNX","APO","AMKR","SFM","SFM.AU","CELH","AAL","HUM","WHR","PPC.AU","EXE","SMMT","OLLI","ENSG"],"gpt_icon":1},{"id":"2484431429","title":"Madrigal Pharmaceuticals (MDGL) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2484431429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484431429?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:26","pubTimestamp":1732019187,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDGL","BK4585","BK4588","COWN","BK4566","BK4207","TD","BK4127"],"gpt_icon":0},{"id":"2484528399","title":"Madrigal Pharmaceuticals gains amid takeover speculation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484528399","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484528399?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:37","pubTimestamp":1731706677,"startTime":"0","endTime":"0","summary":"magicmine/iStock via Getty Images Madrigal Pharmaceuticals  rose 2% in after hours trading amid some takeover speculation. There's speculation that Madrigal  may have attracted interest from a large pharmaceutical company, according to a Betaville \"uncooked\" alert that circulated on Friday.  Madrigal  has a","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212682537/image_1212682537.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212682537/image_1212682537.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4296576-madrigal-pharmaceuticals-gains-amid-takeover-speculation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":[".IXIC","BK4139","BK4585","QLD","NQmain","TQQQ","MNQmain","PSQ","SQQQ","BK4588","MDGL","QID"],"gpt_icon":0},{"id":"2483376958","title":"John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2483376958","media":"GuruFocus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483376958?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:42","pubTimestamp":1731670975,"startTime":"0","endTime":"0","summary":"Overview of the Recent Transaction On September 30, 2024, Paulson & Co., led by John Paulson (Trades, Portfolio), made a significant addition to its investment portfolio by acquiring 192,000 shares of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2605927/john-paulsons-strategic-acquisition-in-madrigal-pharmaceuticals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4585","MDGL","BK4588","BK4139"],"gpt_icon":0},{"id":"2483875159","title":"BRIEF-RTW Investments Reports 9.2% Passive Stake In Madrigal Pharmaceuticals As Of Sept 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483875159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483875159?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:54","pubTimestamp":1731585291,"startTime":"0","endTime":"0","summary":"BRIEF-RTW Investments Reports 9.2% Passive Stake In Madrigal Pharmaceuticals As Of Sept 30, 2024Nov 14 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:RTW INVESTMENTS, LP REPORTS 9.2% PASSIVE STAKE IN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0XG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MDGL","BK4139","BK4585"],"gpt_icon":0},{"id":"2483878793","title":"Rtw Investments, Lp Reports 9.2% Passive Stake in Madrigal Pharmaceuticals Inc as of Sept 30, 2024- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483878793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483878793?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:32","pubTimestamp":1731583975,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0XG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2482738190","title":"Zacks Industry Outlook Madrigal, Corcept, Catalyst  Larimar and  Theravance","url":"https://stock-news.laohu8.com/highlight/detail?id=2482738190","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482738190?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:47","pubTimestamp":1731329220,"startTime":"0","endTime":"0","summary":"Chicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics LRMR and Theravance Biopharma TBPH.The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act . With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely.However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his previous term, had put stress on control of drug prices, though it was not highlighted in his election campaign this time around. Regular pipeline setbacks, slow ramp-up of newer drugs, Federal Trade Commission’s  scrutiny of M&A deals and broader macroeconomic uncertainty are some of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-industry-outlook-madrigal-corcept-124700319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","FA","ESmain","BK4130","BK4539","SPY","BK4559","VOO","BK4581","CPRX","MDGL","BK4007","BK4585","TBPH","FTC","BK4588","BK4504","CORT","SH","LRMR","SPXU","SSO","BK4535","BK4550",".SPX","LU1559883803.SGD","SDS","IVV","BK4532","LU0566484027.USD","BK4139","OEX","OEF","UPRO"],"gpt_icon":0},{"id":"2481103625","title":"5 Small Drug Stocks to Buy as Trump Gets Re-Elected","url":"https://stock-news.laohu8.com/highlight/detail?id=2481103625","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481103625?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:18","pubTimestamp":1731068280,"startTime":"0","endTime":"0","summary":"The ZacksMedical-Drugsindustry comprises small and some medium-sized drug companies that make medicines for both human and veterinary use. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial-stage drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate. For such companies, upfront or milestone payments from collaboration partners — in most cases, their larger counterparts — are the main sources of revenues. These companies need ample free cash flow to fund their R&D activities.Factors Shaping the Future of the Medical-Drugs Industry. Strong Collaboration Partners: These companies regularly seek external partners and collaborators for complementary strengths. A partnership deal with a popular drugmaker is a good sign about the potential of small pharma companies, especially when an equity investment is included in the deal. M&A deals are in full swing in the sec","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-small-drug-stocks-buy-121800348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IVV","OEX","VOO","SPY","BK4559","LU1559883803.SGD","SPXU","TBPH","BK4504","BK4139","BK4585","FTC","LRMR","BK4534","CORT",".SPX","BK4532","BK4588","BK4535","UPRO","SSO","ESmain","OEF","LU0566484027.USD","CPRX","BK4539","BK4550","BK4581","BK4007","BK4130","SDS","SH","MDGL","FA"],"gpt_icon":0},{"id":"2481465186","title":"3 High Growth Tech Stocks Leading The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2481465186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481465186?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:10","pubTimestamp":1730988648,"startTime":"0","endTime":"0","summary":"The United States market has shown robust performance, rising 2.3% over the last week and 35% over the past year, with earnings forecasted to grow by 15% annually. In this thriving environment, a good stock often combines strong growth potential with innovative technology solutions that align well with current market trends and future growth expectations.Top 10 High Growth Tech Companies In The United States. Click here to discover the nuances of ADMA Biologics with our detailed analytical health report.Understand ADMA Biologics' track record by examining our Past report.Operations: Madrigal Pharmaceuticals focuses on developing treatments for non-alcoholic steatohepatitis  in the U.S. As a clinical-stage company, it does not currently generate revenue from product sales.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-high-growth-tech-stocks-141048086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0511384066.AUD","BK4585","BK4588","LU0353189680.USD","LU0353189763.USD","LU2087625088.SGD","ADMA","FICO","BK4023","IE00BLDYK493.USD","MDGL","IE00B64QTZ34.USD","LU0289739343.SGD","LU0289961442.SGD","BK4139","LU0057025933.USD","LU0069063385.USD","LU0472753341.HKD"],"gpt_icon":0},{"id":"2481606089","title":"Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606089","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481606089?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., Nov.  06, 2024  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975656/0/en/Madrigal-Pharmaceuticals-Inc-Announces-Participation-at-Three-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0129},{"period":"1month","weight":-0.0273},{"period":"3month","weight":0.321},{"period":"6month","weight":0.1078},{"period":"1year","weight":0.3875},{"period":"ytd","weight":0.333}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032263},{"month":2,"riseRate":0.75,"avgChangeRate":0.088162},{"month":3,"riseRate":0.25,"avgChangeRate":-0.038862},{"month":4,"riseRate":0.5,"avgChangeRate":0.008688},{"month":5,"riseRate":0.375,"avgChangeRate":0.168822},{"month":6,"riseRate":0.625,"avgChangeRate":0.024173},{"month":7,"riseRate":0.125,"avgChangeRate":-0.088753},{"month":8,"riseRate":0.555556,"avgChangeRate":0.058165},{"month":9,"riseRate":0.333333,"avgChangeRate":0.13282},{"month":10,"riseRate":0.666667,"avgChangeRate":0.070394},{"month":11,"riseRate":0.555556,"avgChangeRate":0.062808},{"month":12,"riseRate":0.444444,"avgChangeRate":0.416237}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}